DGAP-News

AURELIUS reports preliminary numbers for 2014 and plans to raise its dividend to EUR 2.00 per share - Seite 2

million). This is a record amount for AURELIUS.

Plentiful cash reserves, as before

Due in large part to the proceeds collected on the successful sales of
brightONE Healthcare, Connectis, and Framochem in financial year 2014,
AURELIUS held cash and cash equivalents in the record amount of EUR 328.4
million as of year-end 2014 (December 31, 2013: EUR 223.9 million), based
on preliminary numbers. The equity ratio was 26% (December 31, 2013: 29%).

Dividend raised by 90% to EUR 2.00, record pay-out of EUR 63.4 million

As in prior years, the Executive Board would like for the shareholders of
AURELIUS AG to benefit from the company's success in financial year 2014,
and therefore it will propose to the Supervisory Board for the annual
shareholders' meeting to be held on June 15, 2015 that the company pay a
dividend of EUR 2.00 per share from the distributable profit of AURELIUS
AG. The dividend will be composed of a basic dividend of EUR 0.80, which is
14% higher than last year (2013: EUR 0.70), and a special dividend of EUR
1.20, which is 243% higher than last year (2013: EUR 0.35). Thus, the
planned dividend pay-out will amount to EUR 63.4 million (2013: EUR 33.3
million). The reason for the considerably higher special dividend can be
found in the successful company sales in 2014, particularly the sale of the
Healthcare Division of brightONE to T-Systems and the sales of the
Hungarian Framochem and the Swiss connectis AG to strategic investors.

Transaction pipeline is still very well filled

After eight company acquisitions and five company sales in the very busy
year 2014, AURELIUS still disposes of a very well filled transaction
pipeline and is working intensively to close other transactions. Two of
these acquisitions, one of the European operations of the Tavex Group and
one of the European Crafts Division of Coats, have already been announced
in the current year.

Key Figures

                                             01/01 - 12/31/  01/01 - 12/31/
(in euro millions)                                     2014            2013

Consolidated revenues                               1,595.8         1,525.2
Consolidated revenues, annualized                   1,725.3         1,602.2

Consolidated EBITDA                                   207.8            88.6

- thereof bargain purchase income                      70.3            41.2
- thereof restructuring and non-recurring
expenses                                               59.8            58.8